Grifols (GIKLY) Income from Non-Controlling Interests (2010 - 2023)
Grifols (GIKLY) posted Income from Non-Controlling Interests of $130569.6 for Q4 2023, up 103.57% quarter-over-quarter from $64139.9 in Q4 2022, and up 103.57% year-on-year from $64139.9 in Q4 2022.
Grifols (GIKLY) Income from Non-Controlling Interests (2010 - 2023) Analysis & Trends
Grifols (GIKLY) has reported Income from Non-Controlling Interests for 12 consecutive years, with $130569.6 the latest figure, recorded in Q4 2023.
- Income from Non-Controlling Interests for Q4 2023 came in at $130569.6, up 103.57% year-over-year; the trailing twelve-month figure through Dec 2023 was -$18.6 million (down 11.57% YoY), and the FY2025 annual result was $114.1 million, up 90.63% from the prior year.
- Income from Non-Controlling Interests was $130569.6 for Q4 2023 at Grifols, up from $64139.9 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $130569.6 in Q4 2023 and troughed at -$18.9 million in Q1 2020.
- Average Income from Non-Controlling Interests over 4 years is -$4.7 million, with a median of $82649.9 recorded in 2019.
- Year-over-year, Income from Non-Controlling Interests surged 115.33% in 2019 and tumbled 18826.37% in 2020.
- Over 4 years, Income from Non-Controlling Interests stood at $101160.0 in 2019, then sank by 18826.37% to -$18.9 million in 2020, then jumped by 100.34% to $64139.9 in 2022, then jumped by 103.57% to $130569.6 in 2023.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $130569.6 in Q4 2023, $64139.9 in Q4 2022, and -$18.9 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 130,569.61 |
| Dec 31, 2022 | 64,139.89 |
| Mar 31, 2020 | -18.94 Mn |
| Mar 31, 2019 | 101,159.97 |
| Dec 31, 2018 | 2.06 Mn |
| Jun 30, 2018 | 668,328.87 |
| Mar 31, 2018 | -659,722.11 |
| Dec 31, 2017 | -1.22 Mn |
| Jun 30, 2017 | 256,194.99 |
| Mar 31, 2017 | -274,874.98 |
| Dec 31, 2016 | -353,069.82 |
| Sep 30, 2016 | 256,722.43 |
| Jun 30, 2016 | 76,831.50 |
| Dec 31, 2015 | -1.98 Mn |
| Sep 30, 2015 | 201,323.57 |
| Jun 30, 2015 | -278,495.60 |
| Mar 31, 2015 | -754,728.11 |
| Dec 31, 2014 | 833,638.93 |
| Sep 30, 2014 | 848,139.23 |
| Jun 30, 2014 | 721,604.52 |